Antegren Data Show 66% Reduction In Multiple Sclerosis Relapse Rate
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec and Elan are confident that one-year data will differentiate Antegren within the MS market. The companies have three weeks to familiarize prescribers and payors with natalizumab ahead of its estimated FDA action date at the end of the month.
You may also be interested in...
Antegren Launch Will Be “Very Aggressive,” Biogen Idec Says
The company expects marketing expenses to increase into next year to support the launch, including dissemination of two-year Phase III data after mid-2005. First Antegren patients will likely be those who have failed other therapies, CEO Mullen says
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.
CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says
Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.